Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases

Author(s): Chongshan Liao, Chengfei Zhang, Yanqi Yang*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 41 , 2017

Become EABM
Become Reviewer
Call for Editor


Bone remodelling is a strictly regulated dynamic process between bone resorption and bone formation. Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis (SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes the current knowledge of IL-17 signalling pathways. Typical IL-17–mediated bone destruction disorders are examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory loss of bone targeting IL-17.

Keywords: IL-17, IL-17 receptor, bone loss, osteoclastogensis, RANKL, osteoclasts.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 15 February, 2018
Page: [6302 - 6309]
Pages: 8
DOI: 10.2174/1381612823666170519120040
Price: $65

Article Metrics

PDF: 31
PRC: 1